Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Jan. 14, 2025 -- Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without type 2 diabetes, according to a study published online Jan. 31 in JAMA Network Open.

Patricia J. Rodriguez, Ph.D., M.P.H., from Truveta Inc. in Bellevue, Washington, and colleagues conducted a retrospective cohort study involving 125,474 adults with overweight or obesity who newly initiated treatment with a dual-labeled GLP-1 receptor agonist (liraglutide, semaglutide, or tirzepatide) between Jan. 1, 2018, and Dec. 31, 2023. Patients were followed for up to two years to assess discontinuation and for two additional years to examine reinitiation.

The researchers found that compared with those with type 2 diabetes, patients without type 2 diabetes had a significantly higher one-year discontinuation rate (64.8 versus 46.5 percent). Significant associations were seen for higher weight loss and higher income with lower rates of discontinuation; a higher risk for discontinuation was seen in association with moderate or severe incident gastrointestinal adverse events (hazard ratios, 1.38 and 1.19 for those with and without type 2 diabetes, respectively). Of 41,792 patients who discontinued and had a discontinuation weight measurement available, one-year reinitiation was lower for those without versus with type 2 diabetes (36.3 versus 47.3 percent). Increased hazards of reinitiation were seen in association with weight regain of 1 percent from discontinuation (2.3 and 2.8 percent for those with and without type 2 diabetes, respectively).

"Greater weight loss and higher income (type 2 diabetes only) were associated with lower discontinuation, while weight regain since discontinuation was associated with higher reinitiation," the authors write.

Several authors disclosed ties to the health care industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-15 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords